ライフサイエンスコーパス: extracutaneous

1 development of melanoma, both cutaneous and extracutaneous.

2 ceous gland (SG) hypertrophy, hair loss, and extracutaneous abnormalities including growth retardatio

3 be extensive, permanent, and associated with extracutaneous abnormalities.

4 BAFF level was not correlated directly with extracutaneous cGVHD response, although full cutaneous r

5 ioner with their symptoms and any associated extracutaneous clinical or laboratory findings that may

6 ve cutaneous plaque and tumor involvement to extracutaneous compartments of blood, lymph nodes, and v

7 elative risk for the development of specific extracutaneous complications and/or premature death.

8 -based data are now available on the risk of extracutaneous complications in each of the major epider

9 or patient management and preventing further extracutaneous complications.

10 ar OS, 55% and 28%); and FMF presenting with extracutaneous disease (group C; n = 17; 5-year and 10-y

11 There is no evidence of extracutaneous disease at presentation and for 6 months

12 The presence of extracutaneous disease at presentation is the most impor

13 One hundred twelve patients with extracutaneous disease at presentation or with progressi

14 that present in the skin with no evidence of extracutaneous disease at the time of diagnosis.

15 that present in the skin with no evidence of extracutaneous disease at the time of diagnosis.

16 from diagnosis, the risk for progression to extracutaneous disease by initial extent of skin involve

17 es of disease are no longer significant once extracutaneous disease develops.

18 Thus, its effects on systemic immunity and extracutaneous disease manifestations remain poorly unde

19 The primary extracutaneous disease was under control in 95 patients

20 t 5 years, 21% of all patients had developed extracutaneous disease.

21 in in early stages but can be accompanied by extracutaneous dissemination of malignant T cells to the

22 in which skin lesions no longer regress and extracutaneous dissemination often occurs.

23 important role for MEC in the physiology of extracutaneous epithelial tissues, including diverse muc

24 The Lamc2(jeb) mice display additional extracutaneous features such as loss of bone mineralizat

25 notype with characteristic Th1/Th17 skin and extracutaneous immune responses was initiated and mainta

26 e also associated with increased odds of all extracutaneous infections (P < .0001), except recurrent

27 th contribute to susceptibility to warts and extracutaneous infections in children.

28 een childhood AD, atopic disease, warts, and extracutaneous infections suggest that barrier disruptio

29 is associated with increased risk of warts, extracutaneous infections, and other atopic diseases and

30 hout other atopic disease had higher odds of extracutaneous infections, including strep throat, other

31 h might predispose toward both cutaneous and extracutaneous infections.

32 dentify an IL-36/ IFN-I axis contributing to extracutaneous inflammation in psoriasis.

33 malities, cutaneous inflammation can lead to extracutaneous inflammation, resulting in the downstream

34 of 7.6 months as compared with those without extracutaneous involvement (17 patients), who had a more

35 logic and molecular data of 16 children with extracutaneous JXG and 5 adults with xanthogranulomas co

36 Rarely, extracutaneous localizations occur; the genetic drivers

37 ch are the histiocytoid variant), (2) a rare extracutaneous manifestation of Sweet's syndrome with ca

38 Rare fatalities have been reported in extracutaneous manifestation.

39 tribution, and type of musculoskeletal (MSK) extracutaneous manifestations affecting joint and bone w

40 Those with extracutaneous manifestations at presentation (11 patien

41 MSK extracutaneous manifestations occurred in 274 of 1,058 p

42 hematogenously to other organs, resulting in extracutaneous manifestations of Lyme borreliosis, inclu

43 ollowed by Western blot testing, to diagnose extracutaneous manifestations of Lyme disease.

44 The high prevalence of extracutaneous manifestations, along with activation of

45 us, is characterized by cutaneous mucinosis, extracutaneous manifestations, and a monoclonal gammopat

46 ein and differs in severity of skin lesions, extracutaneous manifestations, and performance status.

47 layers of skin and mucous membranes, without extracutaneous manifestations, and thus is nonsyndromic.

48 has been described, with potentially severe extracutaneous manifestations, morbidity and mortality.

49 systemic lupus in addition to cases without extracutaneous manifestations, targeted treatments for D

50 ion of clinical features associated with MSK extracutaneous manifestations.

51 type VII collagen deficits and cutaneous and extracutaneous manifestations.

52 g a negative predictive value of 90% for MSK extracutaneous manifestations.

53 ulating anti-C1q autoantibodies and possible extracutaneous manifestations.

54 period than had been completed previously on extracutaneous MF.

55 ctivation of IFN-I genes was associated with extracutaneous morbidity, in both GPP and PV.

56 (BCCs), skeletal anomalies (SAs), and other extracutaneous neoplasms.

57 full cutaneous responders exhibited improved extracutaneous organ response rates compared with skin n

58 mast cells (MCs) in the bone marrow (BM) and extracutaneous organs.

59 ages, especially hair, as well as a range of extracutaneous pathologies.

60 Objective extracutaneous signs of Lyme disease did not develop in

61 ammalian host, and is primarily expressed in extracutaneous sites during murine infection.

62 on syndrome with aberrant mast cells (MC) at extracutaneous sites has been described in patients with

63 e after the dissemination of the organism to extracutaneous sites in subsequent stages of infection.

64 e from advanced lesions (cutaneous tumors or extracutaneous sites); none of 12 patch/plaque stage CTC

65 f noncontiguous anatomic sites or those with extracutaneous spread.

66 e mitogenesis, as well as lipid synthesis in extracutaneous tissues.

67 lliculotropic MF, extent of skin lesions and extracutaneous transformation were associated with reduc

68 L, the neoplastic CD4(+) lymphocytes acquire extracutaneous tropism, and with disease progression, th

69 ful biomarker of BRAFi-induced cutaneous and extracutaneous tumor formation.

70 nd molecular characterization of 73 skin and extracutaneous tumors in 31 patients who underwent BRAFi

71 PTCH mutations in several types of sporadic extracutaneous tumors.